BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Average Recommendation of “Buy” from Analysts

BioLife Solutions, Inc. (NASDAQ:BLFS) has been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $31.2857.

BLFS has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Zacks Research raised BioLife Solutions to a “strong-buy” rating in a report on Monday, August 11th. Wall Street Zen lowered BioLife Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. Finally, Stephens initiated coverage on BioLife Solutions in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price objective on the stock.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $25.53, for a total transaction of $255,300.00. Following the completion of the sale, the chief marketing officer directly owned 124,618 shares in the company, valued at approximately $3,181,497.54. The trade was a 7.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $24.40, for a total value of $12,200,000.00. Following the sale, the insider owned 6,707,165 shares of the company’s stock, valued at approximately $163,654,826. This trade represents a 6.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,019,020 shares of company stock valued at $47,765,813. 2.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Several large investors have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in BioLife Solutions during the 2nd quarter worth approximately $1,482,000. Thrivent Financial for Lutherans increased its stake in BioLife Solutions by 2.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock worth $588,000 after buying an additional 702 shares in the last quarter. Public Sector Pension Investment Board increased its stake in BioLife Solutions by 10.3% during the 2nd quarter. Public Sector Pension Investment Board now owns 126,465 shares of the medical equipment provider’s stock worth $2,724,000 after buying an additional 11,769 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in BioLife Solutions by 9.8% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 34,692 shares of the medical equipment provider’s stock worth $747,000 after buying an additional 3,110 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in BioLife Solutions by 547.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after buying an additional 6,032 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $25.05 on Friday. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -208.73 and a beta of 1.76. The business has a 50 day simple moving average of $22.69 and a 200-day simple moving average of $23.36. BioLife Solutions has a 1 year low of $19.10 and a 1 year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The business had revenue of $25.42 million during the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, analysts expect that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.